All In Biotech

Drug Trial Radar · NCT07335562

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Feb 3, 2027

Primary completion

Nov 14, 2028

Study completion Nov 11, 2030

Sponsor

Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Celgene Corporation
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis

Conditions

  • Systemic Sclerosis

Interventions

  • BMS-986353Drug

    Specified dose on specified days

  • FludarabineDrug

    Specified dose on specified days

  • CyclophosphamideDrug

    Specified dose on specified days

  • TocilizumabDrug

    Specified dose on specified days

  • RituximabDrug

    Specified dose on specified days

  • NintedanibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The absolute change from baseline in Forced Vital Capacity (FVC) in mLTime frame: At 12 months

Locations

56 sites in 10 countries. Site status is shown where the registry gives one.

  • Local Institution - 0035

    Scottsdale, Arizona

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Local Institution - 0069

    Miami, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Local Institution - 0139

    Chicago, Illinois

  • Local Institution - 0084

    Worcester, Massachusetts

  • Local Institution - 0034

    Ann Arbor, Michigan

  • Local Institution - 0037

    Rochester, Minnesota

  • Local Institution - 0082

    Summit, New Jersey

  • Cleveland Clinic

    Cleveland, Ohio

  • Local Institution - 0142

    Philadelphia, Pennsylvania

  • Local Institution - 0143

    Pittsburgh, Pennsylvania

  • Local Institution - 0002

    Charleston, South Carolina

  • Local Institution - 0074

    Dallas, Texas

  • Local Institution - 0144

    Houston, Texas

  • Local Institution - 0008

    Seattle, Washington

  • Local Institution - 0080

    Liège, Belgium

  • Local Institution - 0057

    Leuven, Vlaams-Brabant, Belgium

  • Local Institution - 0104

    Halifax, Nova Scotia, Canada

  • Local Institution - 0088

    Sherbrooke, Quebec, Canada

  • Local Institution - 0049

    Bordeaux, France

  • Local Institution - 0012

    Bron, France

  • Local Institution - 0052

    Paris, France

  • Local Institution - 0141

    Rennes, France

  • Local Institution - 0031

    Strasbourg, Alsace, France

  • Local Institution - 0061

    Toulouse, Haute-Garonne, France

  • Local Institution - 0046

    Berlin, Germany

  • Local Institution - 0016

    Cologne, Germany

  • Local Institution - 0028

    Erlangen, Germany

  • Local Institution - 0042

    Leipzig, Germany

  • Local Institution - 0032

    München, Germany

  • Local Institution - 0033

    Tübingen, Germany

  • Local Institution - 0038

    Würzburg, Germany

  • Local Institution - 0106

    Milan, Italy

  • Local Institution - 0103

    Rome, Lazio, Italy

  • Local Institution - 0004

    Milan, Milano, Italy

  • Local Institution - 0108

    Pisa, Tuscany, Italy

  • Local Institution - 0123

    Fukuoka, Japan

  • Local Institution - 0136

    Maebashi, Japan

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.